Role of PSMA-ligands Imaging in Renal Cell Carcinoma Management: Current Status and Future Perspectives

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2022 Feb 26

PMID 35217902

Authors

Luca Urso

Angelo Castello

Giovanni Christian Rocca

Federica Lancia

Stefano Panareo

Corrado Cittanti

Licia Uccelli

Luigia Florimonte

Massimo Castellani

Carmelo Ippolito

Antonio Frassoldati

Mirco Bartolomei

Affiliations

Soon will be listed here.

Abstract

Background: Renal masses detection is continually increasing worldwide, with Renal Cell Carcinoma (RCC) accounting for approximately 90% of all renal cancers and remaining one of the most aggressive urological malignancies. Despite improvements in cancer management, accurate diagnosis and treatment strategy of RCC by computed tomography (CT) and magnetic resonance imaging (MRI) are still challenging. Prostate-Specific Membrane Antigen (PSMA) is known to be highly expressed on the endothelial cells of the neovasculature of several solid tumors other than prostate cancer, including RCC. In this context, recent preliminary studies reported a promising role for positron emission tomography (PET)/CT with radiolabeled molecules targeting PSMA, in alternative to fluorodeoxyglucose (FDG) in RCC patients.

Purpose: The aim of our review is to provide an updated overview of current evidences and major limitations regarding the use of PSMA PET/CT in RCC.

Methods: A literature search, up to 31 December 2021, was performed using the following electronic databases: PubMed, SCOPUS, Web of Science, and Google Scholar.

Results: The findings of this review suggest that PSMA PET/CT could represent a valid imaging option for diagnosis, staging, and therapy response evaluation in RCC, particularly in clear cell RCC.

Conclusions: Further studies are needed for this "relatively" new imaging modality to consolidate its indications, timing, and practical procedures.

Citing Articles

Vesicles Secreted by Renal Cell Carcinoma Cells Cause Vascular Endothelial Cells to Express PSMA and Drive Tumor Progression.

Watanabe R, Kagimoto K, Chosei M, Sakaue T, Kurata M, Miura N Cells. 2025; 14(3).

PMID: 39936957 PMC: 11817738. DOI: 10.3390/cells14030165.

Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.

Jozwik-Plebanek K, Saracyn M, Kolodziej M, Kaminska O, Durma A, Madra W Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770563 PMC: 11678666. DOI: 10.3390/ph17121721.

ESR Bridges: renal cell carcinoma-a multidisciplinary view.

Miron Mombiela R, Thomsen F, Fuglo D, Hasselager T, Moller A Eur Radiol. 2024; .

PMID: 39661148 DOI: 10.1007/s00330-024-11270-w.

Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.

Muglia V, Laschena L, Pecoraro M, de Lion Gouvea G, Colli L, Panebianco V Abdom Radiol (NY). 2024; 50(2):807-826.

PMID: 39254707 DOI: 10.1007/s00261-024-04412-7.

The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.

Filippi L, Urso L, Ferrari C, Guglielmo P, Evangelista L Eur J Nucl Med Mol Imaging. 2024; 52(1):263-279.

PMID: 39110196 PMC: 11599309. DOI: 10.1007/s00259-024-06866-9.

References

Baccala A, Sercia L, Li J, Heston W, Zhou M . Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007; 70(2):385-90. DOI: 10.1016/j.urology.2007.03.025. View

Rowe S, Gorin M, Hammers H, Som Javadi M, Hawasli H, Szabo Z . Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med. 2015; 29(10):877-82. PMC: 4666821. DOI: 10.1007/s12149-015-1017-z. View

Hou G, Zhao D, Jiang Y, Zhu Z, Huo L, Li F . Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Cancer Imaging. 2021; 21(1):25. PMC: 7908760. DOI: 10.1186/s40644-021-00393-8. View

Uijen M, Derks Y, Merkx R, Schilham M, Roosen J, Prive B . PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021; 48(13):4350-4368. PMC: 8566635. DOI: 10.1007/s00259-021-05433-w. View

Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A . Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2016; 38(2):156-163. DOI: 10.1097/MNM.0000000000000618. View

Giesel F, Will L, Paddubny K, Kremer C, Rathke H, Radtke J . [18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clin Genitourin Cancer. 2017; 16(2):111-113. DOI: 10.1016/j.clgc.2017.11.008. View

Pichler R, Heidegger I . Novel concepts of antiangiogenic therapies in metastatic renal cell cancer. Memo. 2017; 10(4):206-212. PMC: 5725523. DOI: 10.1007/s12254-017-0344-2. View

Foley R, Redman S, Graham R, Loughborough W, Little D . Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol. 2020; 75(12):903-913. DOI: 10.1016/j.crad.2020.06.031. View

Hendrikse N, Franssen E, van der Graaf W, Meijer C, Piers D, Vaalburg W . 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998; 77(3):353-8. PMC: 2151293. DOI: 10.1038/bjc.1998.57. View

10.

Raveenthiran S, Esler R, Yaxley J, Kyle S . The use of Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019; 46(11):2280-2288. DOI: 10.1007/s00259-019-04432-2. View

11.

Zhang H, Koumna S, Pouliot F, Beauregard J, Kolinsky M . PSMA Theranostics: Current Landscape and Future Outlook. Cancers (Basel). 2021; 13(16). PMC: 8391520. DOI: 10.3390/cancers13164023. View

12.

Toyama Y, Werner R, Ruiz-Bedoya C, Ordonez A, Takase K, Lapa C . Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon. Theranostics. 2021; 11(12):6105-6119. PMC: 8058716. DOI: 10.7150/thno.58682. View

13.

Gormley T, Van Every M, Moreno A . Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging. Urology. 1996; 48(1):33-9. DOI: 10.1016/s0090-4295(96)00095-7. View

14.

Golan S, Aviv T, Groshar D, Yakimov M, Zohar Y, Prokocimer Y . Dynamic Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study. J Nucl Med. 2020; 62(6):773-778. DOI: 10.2967/jnumed.120.251272. View

15.

Seitz A, Rauscher I, Haller B, Kronke M, Luther S, Heck M . Preliminary results on response assessment using Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2017; 45(4):602-612. DOI: 10.1007/s00259-017-3887-x. View

16.

Mittlmeier L, Unterrainer M, Rodler S, Todica A, Albert N, Burgard C . F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. Eur J Nucl Med Mol Imaging. 2020; 48(6):2031-2037. PMC: 8113284. DOI: 10.1007/s00259-020-05165-3. View

17.

Ozulker T, Ozulker F, Ozbek E, Ozpacaci T . A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun. 2011; 32(4):265-72. DOI: 10.1097/MNM.0b013e3283442e3b. View

18.

Wang H, Ding H, Chen J, Chao C, Lu Y, Lin W . Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012; 12:464-74. PMC: 3483599. DOI: 10.1102/1470-7330.2012.0042. View

19.

Chen R, Zhou X, Huang G, Liu J . Fructose 1,6-Bisphosphatase 1 Expression Reduces F-FDG Uptake in Clear Cell Renal Cell Carcinoma. Contrast Media Mol Imaging. 2019; 2019:9463926. PMC: 6339721. DOI: 10.1155/2019/9463926. View

20.

Rhee H, Blazak J, Tham C, Ng K, Shepherd B, Lawson M . Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016; 6(1):76. PMC: 5075321. DOI: 10.1186/s13550-016-0231-6. View